Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Three Months Ended September 30, 2025						Nine Months Ended September 30, 2025
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over Time	$	—	$	—	$	—	$	325	$	—	$	325
Total Drug Products	—		—		—		325		—		325
Concentrate Products
Product Sales – Point-in-time	15,927		13,824		2,103		50,587		44,449		6,138
Total Concentrate Products	15,927		13,824		2,103		50,587		44,449		6,138
Net Revenue	$	15,927	$	13,824	$	2,103	$	50,912	$	44,449	$	6,463

In thousands	Three Months Ended September 30, 2024						Nine Months Ended September 30, 2024
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over Time	$	11	$	—	$	11	$	34	$	—	$	34
Total Drug Products	11		—		11		34		—		34
Concentrate Products
Product Sales – Point-in-time	28,305		26,247		2,058		76,790		70,390		6,400
Total Concentrate Products	28,305		26,247		2,058		76,790		70,390		6,400
Net Revenue	$	28,316	$	26,247	$	2,069	$	76,824	$	70,390	$	6,434

Schedule of Contract Balance

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	September 30, 2025		December 31, 2024		January 1, 2024
Accounts Receivable, net	$	8,328	$	8,291	$	10,901
Contract Liabilities, which are included in deferred license revenue	$	—	$	475	$	521